Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

iShares Select Dividend ETF offers a stable 3.5% yield backed by durable U.S. company dividends.

Market News
24 May 2026
24/7 Wall Street
View Source
Bullish
pluang ai news

The iShares Select Dividend ETF (DVY) provides a reliable income stream with a trailing yield of about 3.5%, sourced from dividends of roughly 100 U.S. companies known for stable payouts. Its portfolio focuses on defensive sectors like utilities, financials, and consumer staples, with no leverage or complex strategies involved. Despite rising Treasury yields potentially limiting price gains, DVY's dividend payments are safe and have trended upward since 2003, making it suitable for retirees seeking steady income from U.S. equities at a low cost. Investors seeking higher yields may need to consider riskier options.

More News (PFE)

SPHD ETF offers steady monthly dividends with a 4.5% yield but growth may fluctuate with market shifts.

SPHD ETF offers steady monthly dividends with a 4.5% yield but growth may fluctuate with market shifts.

The Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) provides monthly income with a current 4.5% yield, focusing on stable, high-yield stocks from the S&P 500. Its dividends come from real cash flows of companies like Pfizer and Verizon, thoug...

Market News
Neutral
1 day ago
Pfizer's growth and cost savings boost revenues and dividends, making it a strong buy for patient investors.

Pfizer's growth and cost savings boost revenues and dividends, making it a strong buy for patient investors.

Pfizer's aggressive mergers and acquisitions combined with in-house research and development have driven its growth portfolio to generate $3.1 billion in revenues in the first quarter of 2026, a 22% operational increase year-over-year. The risk from ...

Analyst Insights
Bullish
2 days ago
Pfizer advances pneumococcal vaccine with strong Phase 2 results, starts Phase 3 in infants.

Pfizer advances pneumococcal vaccine with strong Phase 2 results, starts Phase 3 in infants.

Pfizer reported positive Phase 2 results for its 25-valent pneumococcal conjugate vaccine, showing much stronger immune responses against serotype 3 compared to PREVNAR 20. The vaccine could cover up to 90% of disease-causing serotypes in children un...

Company Fundamentals
Bullish
4 days ago
Johnson & Johnson offers more stable returns and dividend growth than Pfizer despite Pfizer's higher yield.

Johnson & Johnson offers more stable returns and dividend growth than Pfizer despite Pfizer's higher yield.

Johnson & Johnson (JNJ) is seen as having a superior return and risk profile compared to Pfizer (PFE), mainly due to its consistent dividend growth over 63 years, lower payout ratio, ongoing share buybacks, and stable inventory levels. While Pfizer o...

Company Fundamentals
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App